Acute generalized exanthematous pustulosis after COVID ‐19 treatment with hydroxychloroquine
Year: 2020
Type: letter
Abstract: Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquineDear Editor, Hydroxychloroquine (HCQ) was recently suggested for both chemoprophylaxis and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.1 However, data on the safety profile of HCQ in coronavirus disease-19 (COVID-19) treatment is still scarce, especially if millions of patients would be exposed to HCQ.As of April 29, 2020, the total number of confirmed COVID-19 cases exceeded 3 million.2 If HCQ treatment is prescribed massively for COVID-19 chemoprophylaxis and treatment, rare and severe side effects related to treatment would become more prevalent.Adverse effects of HCQ include exanthema, stomatitis, itching, and hyperpigmentation.3 Severe side effects encompass Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis (AGEP).3,4 The latter is the most frequently reported serious side effect related to HCQ. 3 We would like to share our experience from Tunisia.As of April 26, 2020, there are 967 accumulated COVID-19 cases.5 A total of 211 cases were diagnosed in Tunis.Among these cases, there was an interesting case of a 39-year-old female patient who developed AGEP after COVID-19 treatment with HCQ.She was hospitalized on March 31 for COVID-19 management.The diagnosis was confirmed after naso-
Source: Dermatologic Therapy
DOI: 10.1111/dth.13565
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3025199808